Somatostatin analogs - From new molecules to new applications

Current Opinion in Pharmacology

Volumn 4, Issue 6, 2004, Pages 608-613

  Pawlikowski, Marek ^a   Mełeń Mucha, Gabriela ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23244; BIM 23A 387; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; HYPOTHALAMUS RELEASE INHIBITING FACTOR; OCTREOTATE[3 TYROSINE]; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PASIREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; CUSHING SYNDROME; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HODGKIN DISEASE; HORMONE ACTION; HUMAN; LIVER CELL CARCINOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SINGLE DRUG DOSE; TREATMENT FAILURE; TUMOR CELL DESTRUCTION; TUMOR LOCALIZATION;

ANIMALS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; POLAND; SOMATOSTATIN;

EID: 13944277784     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.06.010     Document Type: Review

References (24)

1. A. Danoff D. Kleinberg Somatostatin analogs as primary medical therapy for acromegaly Endocrine 20 2003 291-297
2. A. Colao M. Filippella C. Di Somma S. Manzi F. Rota R. Pivonello M. Gaccione M. DeRosa G. Lombardi Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas Endocrine 20 2003 279-283
3. W.W. De Herder S.W.J. Lamberts Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors Endocrine 20 2003 285-290
4. M. Pawlikowski G. Mełeń-Mucha Perspectives of new potential therapeutic applications of somatostatin analogs Neuroendocrinol Lett 24 2003 21-27
5. E.A. Woltering Development of targeted somatostatin-based antiangiogenic therapy: A review and future perspectives Cancer Biother Radiopharm 18 2003 601-609
6. S. Gao B.P. Yu W.G. Dong H.S. Luo Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase World J Gastroenterol 9 2003 2362-2365
7. T. Florio S. Thellung A. Corsaro L. Bocca S. Arena A. Pattarozzi F. Diana D. Schettini F. Barbieri J.L. Ravetti et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro Clin Endocrinol (Oxf) 59 2003 115-128
8. 90Y: Peptide receptor radionuclide therapy results in vitro Cancer Biother Radiopharm 18 2003 761-768
9. A. Colao P. Marzullo A. Cuocolo L. Spinelli R. Pivonello D. Bonaduce M. Salvatore G. Lombardi Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide Clin Endocrinol (Oxf) 58 2003 169-176
10. J. Garland J.R. Buscombe C. Bouvier P. Bouloux M.H. Chapman A.C. Chow N. Reynolds M.E. Caplin Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: A 3-year experience Aliment Pharmacol Ther 17 2003 437-444
11. J.M. Schwartz J.M. Ham Treatment of hepatocellular carcinoma Curr Treat Options Gastroenterol 6 2003 465-472
12. G.I. Uwaifo C.A. Koch B. Hirshberg C.C. Chen P. Hartzband L.K. Nieman K. Pacak Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome? J Endocrinol Invest 26 2003 710-717
13. A.J. Van der Lely W.W. de Herder E.P. Krenning D.J. Kwekkeboom Octreoscan radioreceptor imaging Endocrine 20 2003 307-311
14. A. Saveanu G. Gunz H. Dufour P. Caron F. Fina L. Ouafik M.D. Culler J.P. Moreau A. Enjalbert P. Jaquet BIM-23244, a somatostatin receptor subtype 2- and 5 selective analog with enhanced efficacy in suppressing growth hormone from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab 86 2001 140-145
15. L.J. Hofland J. van der Hoek P.M. van Koetsveld W.W. de Herder M. Waaijers D. Sprij-Kooij C. Bruns G. Weckbecker R. Feelders A.J. van der Lely et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro J Clin Endocrinol Metab 89 2004 1577-1585
16. M. Rocheville D.C. Lange U. Kumar S.C. Patel R.C. Patel Y.C. Patel Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity Science 288 2000 154-157
17. A. Saveanu E. Lavaque C. Gunz A. Barlier S. Kim J.E. Taylor M.D. Culler A. Enjalbert P. Jaquet Demonstration of enhanced potency of a chimeric somatostatin/dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J Clin Endocrinol Metab 87 2002 5545-5552
18. S.G. Ren S. Kim J. Taylor J. Dong J.P. Moreau M.D. Culler S. Melmed Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand J Clin Endocrinol Metab 88 2003 5414-5421
19. Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Culler MD, Pawlikowski M: The effect of selective sst1, sst2, sst 5 somatostatin receptors agonists and a somatostatin/dopamine chimera on the 'clinically non-functioning' pituitary adenomas in vitro. 11th Meeting of the European Neuroendocrine Association, Sorrento-Napoli (Italy), April 24-27 2004 [Abstract P14.280]
20. M. Tejeda Gaal K. Barna O. Csuka G.Y. Keri The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts Anticancer Res 23 2003 4061-4066
21. B. Szende G.Y. Keri TT232: A somatostatin structural derivative as a potent antitumor drug candidate Anticancer Drugs 14 2003 586-588
22. J. Van der Hoek W.W. de Herder R.A. Feelders A.J. van der Lely P. Uitterrlinden V. Boerlin C. Bruns K.W. Poon I. Lewis G. Weckbecker et al. A single-dose comparison of acute effects between the new somatostatin analog SOM230 and ocreotide in acromegalic patients J Clin Endocrinol Metab 89 2004 638-645
23. M. Pawlikowski H. Pisarek J. Kunert-Radek A. Radek Immunohistochemical detection of somatostatin receptor subtypes in 'clinically nonfunctioning' pituitary adenomas Endocr Pathol 14 2003 231-238
24. J. Mundschenk N. Unger S. Schulz V. Hollt S. Schulz R. Steinke H. Lehnert Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy J Clin Endocrinol Metab 88 2003 5150-5157